ReviewFrontiers in endocrinology2025
Metabolic regulation of obesity by naturally occurring compounds: mechanisms and therapeutic potential.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Dietary Bioactive Compounds: Cellular Sensory Pathways, Microbial Partners, and Clinical Realities.Nutrients · 2026Review
- Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.Nutrients · 2026Review
- Resveratrol Attenuates Obesity by Inducing GDF15 Expression via the p38-ATF3 Signaling Pathway.Food science & nutrition · 2026Article
- Dual Activation of GLP-1 and AMPK Pathways by a Multi-Botanical Formulation Improves Obesity and Metabolic Dysfunction in Experimental Models.Nutrients · 2026Article
- Adipose Tissue Plasticity and Adipogenesis: From Cellular Mechanisms to Therapeutic Targets in Obesity.Current obesity reports · 2026Review
- Phytochemicals and Obesity: A mini Review from the Dietary Phytochemical Index Perspective.Current nutrition reports · 2026Review
- Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.Food science & nutrition · 2026Review
- Anti-Inflammatory Properties of Resveratrol.International journal of molecular sciences · 2025Review
- Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global obesity epidemic continues to escalate, driving demands for safer and more effective therapeutic strategies. This review evaluates the potential of natural bioactive compounds as multi-targeted interventions for obesity management. Plant-derived polyphenols (e.g., epigallocatechin-3-gallate (EGCG), resveratrol), alkaloids (e.g., berberine), and marine carotenoids (e.g., fucoxanthin) demonstrate remarkable capacity to modulate fundamental obesity pathways through (A) suppression of adipogenesis via PPARγ and C/EBPα inhibition, (B) activation of lipolysis through hormone-sensitive lipase (HSL) stimulation and AMPK phosphorylation, (C) enhancement of thermogenesis via UCP1 upregulation, and (D) gut microbiome modulation through SCFA production. Clinical evidence supports the efficacy of selected compounds, with green tea catechins showing 4% to 5% body fat reduction and berberine demonstrating significant metabolic improvements. These natural agents offer distinct advantages over conventional drugs through their pleiotropic mechanisms and favorable safety profiles. However, bioavailability limitations and inter-individual variability present significant challenges. Innovative delivery systems, including nanoencapsulation and phospholipid complexes, show promise to enhance the therapeutic potential. The review highlights emerging strategies combining microbiome modulation with precision nutrition approaches while emphasizing the need for standardized clinical protocols. By bridging ethnopharmacological knowledge with modern scientific validation, natural compounds represent a promising avenue to develop sustainable, multi-targeted anti-obesity therapies that address both physiological and metabolic aspects of this complex disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.